scholarly journals Development of a Pharmacoeconomic Model to Assess the Cost Effectiveness of Pharmacogenomics Tests in Chronic Heart Failure: The Case of Ivabradine

2016 ◽  
Vol 19 (3) ◽  
pp. A48-A49
Author(s):  
AC Iliza ◽  
F Fanton Aita ◽  
D Mitchell ◽  
JR Guertin ◽  
A Matteau ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Chronic Heart Failure ◽  
Pharmacoeconomic Model ◽  
The Cost

COST-EFFECTIVENESS OF TELEHEALTH INTERVENTIONS FOR CHRONIC HEART FAILURE PATIENTS: A LITERATURE REVIEW

2014 ◽  
Vol 30 (1) ◽  
pp. 59-68 ◽  
Author(s):  
Andrija S. Grustam ◽  
Johan L. Severens ◽  
Jan van Nijnatten ◽  
Ron Koymans ◽  
Hubertus J. M. Vrijhoef
Keyword(s):  
Heart Failure ◽  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Chronic Heart Failure ◽  
Data Extraction ◽  
Primary Study ◽  
Heart Failure Patients ◽  
Telehealth Intervention ◽  
The Cost

Objectives: Evidence exists that telehealth interventions (e.g., telemonitoring, telediagnostics, telephone care) in disease management for chronic heart failure patients can improve medical outcomes, and we aim to give an overview of the cost-effectiveness of these interventions.Methods: Based on the literature search on “heart failure” in combination with “cost” and “telehealth” we selected 301 titles and abstracts. Titles and abstracts were screened for a set of inclusion criteria: telehealth intervention, heart failure as the main disease, economic analysis present and a primary study performed. In the end, thirty-two studies were included for full reading, data extraction, and critical appraisal of the economic evaluation.Results: Most studies did not present a comprehensive economic evaluation, consisting of the comparison of both costs and effects between telehealth intervention and a comparator. Data on telehealth investment costs were lacking in many studies. The few studies that assessed costs and consequences comprehensively showed that telehealth interventions are cost saving with slight improvement in effectiveness, or comparably effective with similar cost to usual care. However, the methodological quality of the studies was in general considered to be low.Conclusions: The cost-effectiveness of telehealth in chronic heart failure is hardly ascertained in peer reviewed literature, the quality of evidence is poor and there was a difficulty in capturing all of the consequences/effects of telehealth intervention. We believe that without full economic analyses the cost-effectiveness of telehealth interventions in chronic heart failure remains unknown.

Economic evaluation of a nurse-led home and clinic-based secondary prevention programme to prevent progressive cardiac dysfunction in high-risk individuals: The Nurse-led Intervention for Less Chronic Heart Failure (NIL-CHF) randomized controlled study

2017 ◽  
Vol 17 (5) ◽  
pp. 439-445 ◽  
Author(s):  
Shoko Maru ◽  
Joshua Byrnes ◽  
Melinda J Carrington ◽  
Yih-Kai Chan ◽  
Simon Stewart ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Chronic Heart Failure ◽  
Cardiac Dysfunction ◽  
Standard Care ◽  
Controlled Study ◽  
Randomized Controlled ◽  
Life Years ◽  
Hospitalization Costs ◽  
The Cost

Objective: The objective of this study was to assess the cost-effectiveness of a long-term, nurse-led, multidisciplinary programme of home/clinic visits in preventing progressive cardiac dysfunction in patients at risk of developing de novo chronic heart failure (CHF). Methods: A trial-based analysis was conducted alongside a pragmatic, single-centre, open-label, randomized controlled trial of 611 patients (mean age: 66 years) with subclinical cardiovascular diseases (without CHF) discharged to home from an Australian tertiary referral hospital. A nurse-led home and clinic-based programme (NIL-CHF intervention, n = 301) was compared with standard care ( n=310) in terms of life-years, quality-adjusted life-years (QALYs) and healthcare costs. The uncertainty around the incremental cost and QALYs was quantified by bootstrap simulations and displayed on a cost-effectiveness plane. Results: During a median follow-up of 4.2 years, there were no significant between-group differences in life-years (−0.056, p=0.488) and QALYs (−0.072, p=0.399), which were lower in the NIL-CHF group. The NIL-CHF group had slightly lower all-cause hospitalization costs (AUD$2943 per person; p=0.219), cardiovascular-related hospitalization costs (AUD$1142; p=0.592) and a more pronounced reduction in emergency/unplanned hospitalization costs (AUD$4194 per person; p=0.024). When the cost of intervention was added to all-cause, cardiovascular and emergency-related readmissions, the reductions in the NIL-CHF group were AUD$2742 ( p=0.313), AUD$941 ( p=0.719) and AUD$3993 ( p=0.046), respectively. At a willingness-to-pay threshold of AUD$50,000/QALY, the probability of the NIL-CHF intervention being better-valued was 19%. Conclusions: Compared with standard care, the NIL-CHF intervention was not a cost-effective strategy as life-years and QALYs were slightly lower in the NIL-CHF group. However, it was associated with modest reductions in emergency/unplanned readmission costs.

scholarly journals 176 The Cost-Effectiveness of Dapagliflozin for Chronic Heart Failure in Australia

2020 ◽  
Vol 29 ◽  
pp. S114
Author(s):  
F. Savira ◽  
B. Wang ◽  
A. Kompa ◽  
Z. Ademi ◽  
A. Owen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Chronic Heart Failure ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document